JP2013538566A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538566A5
JP2013538566A5 JP2013523643A JP2013523643A JP2013538566A5 JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5 JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
dom7h
acid sequence
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013523643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/063999 external-priority patent/WO2012020143A1/en
Publication of JP2013538566A publication Critical patent/JP2013538566A/ja
Publication of JP2013538566A5 publication Critical patent/JP2013538566A5/ja
Pending legal-status Critical Current

Links

JP2013523643A 2010-08-13 2011-08-12 改良された抗血清アルブミン結合変異体 Pending JP2013538566A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37339710P 2010-08-13 2010-08-13
US61/373,397 2010-08-13
PCT/EP2011/063999 WO2012020143A1 (en) 2010-08-13 2011-08-12 Improved anti-serum albumin binding variants

Publications (2)

Publication Number Publication Date
JP2013538566A JP2013538566A (ja) 2013-10-17
JP2013538566A5 true JP2013538566A5 (enExample) 2014-09-18

Family

ID=44582954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523643A Pending JP2013538566A (ja) 2010-08-13 2011-08-12 改良された抗血清アルブミン結合変異体

Country Status (4)

Country Link
US (2) US9012609B2 (enExample)
EP (1) EP2603522A1 (enExample)
JP (1) JP2013538566A (enExample)
WO (1) WO2012020143A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
MX2012004793A (es) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Variantes de albumina.
JP5969458B2 (ja) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
US9012609B2 (en) * 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
KR20150082422A (ko) 2012-11-08 2015-07-15 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
EP3044232A1 (en) * 2013-09-13 2016-07-20 Novozymes Biopharma DK A/S Albumin variants
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
EP3974449A1 (en) * 2015-11-13 2022-03-30 Ablynx NV Improved serum albumin-binding immunoglobulin variable domains
EP3458034A4 (en) 2016-05-18 2020-01-01 ModernaTX, Inc. POLYNUCLEOTIDES ENCODING RELAXIN
CN117164710A (zh) * 2016-12-07 2023-12-05 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
ES2991459T3 (es) 2017-01-17 2024-12-03 Ablynx Nv Ligantes de albúmina sérica mejorados
SG10202108973SA (en) 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
AU2018220516B2 (en) 2017-02-16 2025-03-06 Sonnet BioTherapeutics, Inc. Albumin binding domain fusion proteins
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291189B1 (en) 1994-05-10 2001-09-18 Carta Proteomics, Inc. Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites
US5658739A (en) 1994-05-10 1997-08-19 The Regents Of The University Of California Method for characterization of the fine structure of protein binding sites
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003277423A1 (en) 2002-10-18 2004-05-04 The Regents Of The University Of California Methods for crystallographic structure determination employing hydrogen exchange analysis
PT1737962E (pt) 2004-03-24 2010-12-03 Domantis Ltd Sequência líder universal gas1
KR20120133403A (ko) 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CA2589800A1 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
KR20100018040A (ko) * 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
DE112008003232T5 (de) 2007-11-30 2011-02-24 Glaxo Group Limited, Greenford Antigen-Bindungskonstrukte
US8685895B2 (en) * 2008-12-05 2014-04-01 Carolyn Enever Methods for selecting protease resistant polypeptides
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
EA027866B1 (ru) * 2009-02-19 2017-09-29 Глэксо Груп Лимитед Улучшенные связывающие сывороточный альбумин варианты
AU2010215482B2 (en) * 2009-02-19 2014-02-13 Glaxo Group Limited Improved anti-serum albumin binding variants
BR112012001681A2 (pt) 2009-07-16 2019-09-24 Graxo Group Ltd domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
BR112012007374A2 (pt) * 2009-09-30 2019-09-24 Glaxo Group Ltd composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante
US9012609B2 (en) * 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants

Similar Documents

Publication Publication Date Title
JP2013538566A5 (enExample)
JP7219220B2 (ja) 改善された血清アルブミン結合剤
RU2577228C2 (ru) Анти-il-17-антитела, способ их получения и способ применения
JP2013529080A5 (enExample)
JP2016539096A5 (enExample)
JP2017520575A5 (enExample)
HRP20161043T1 (hr) Ljudska antitijela visokog afiniteta u odnosu na ljudski angiopoietin-2
FI2691417T4 (fi) Vasta-aineen Fc-variantteja
RS66173B1 (sr) Poboljšana veziva serumskog albumina
JP2010526028A5 (enExample)
JP2013537416A5 (enExample)
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
RU2019123112A (ru) Анти-il-5 антитела
CN104245736B (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
RU2017144098A (ru) Гетеродимеризованный полипептид
JP2017506075A5 (enExample)
JP2013519721A5 (enExample)
IL276286B1 (en) FC variants with improved binding to FCRN and extended half-life
CN115397852B (zh) 工程化抗il-2抗体
JP2009539349A5 (enExample)
JP2015530983A5 (enExample)
JP2021530207A (ja) 二重特異性抗体及びその使用
JP2018509887A5 (enExample)
JP2014534237A5 (enExample)
JP2014530001A5 (enExample)